- Home
- SABA vs SLN Comparison
SABA vs SLN Comparison
Compare SABA & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | SLN |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.6M | 236.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SABA | SLN |
|---|---|---|
| Price | $8.10 | $7.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 91.7K | ★ 221.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.72 | $1.97 |
| 52 Week High | $9.46 | $7.91 |
Technical Indicators
Market Signals| Indicator | SABA | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 69.15 |
| Support Level | $7.97 | $5.79 |
| Resistance Level | $8.27 | $7.40 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 55.59 | 73.22 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.